Alzheimer's Assocation Research only
All of
  • Go to
  • Research Center
  • AAIC
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Research Grants 2012

To view an abstract, select an author from the vertical list on the left.

2012 Grants - Kitazawa

Neuroinflammation-Induced Alterations of GLT-1 and Synaptotoxicity in Alzheimer's Disease

Masashi Kitazawa, Ph.D.
University of California, Merced
Merced, California

2012 New Investigator Research Grant

Astrocytes are "helper" cells in the brain that play a variety of roles. For example, they help support the function of neurons by providing energy to these cells. Recent studies have found that astrocytes may also prevent a toxic process called excitotoxicity in synapses—the tiny channels through which brain cells communicate with one another. Excitotoxicity occurs when synapses become overstimulated, and it can lead to brain cell dysfunction and death in Alzheimer's disease. This toxic overstimulation may begin early in the disease process, and it may result from astrocytes becoming dysfunctional. Specifically, astrocytes may lose their ability to transport a neurotransmitter (or chemical messenger) called glutamate. This, in turn, may lead to abnormal glutamate concentration around synapses, which may cause synaptic loss and brain cell death.

In preliminary studies with Alzheimer's-like mice, Masashi Kitazawa, Ph.D., and colleagues have found that as the animals age or their dementia progresses, they show reduced levels a protein called glutamate transporter-1 (GLT-1). Astrocytes need this protein to remove excess glutamate in the brain. The team also found that they could moderate GLT-1 losses by blocking the activities of another protein called interleukin-1. In a related experiment with cultured cells, the researchers observed that beta-amyloid—a protein fragment implicated in Alzheimer's—could repress GLT-1 expression in neurons. These findings suggest that as brain beta-amyloid proliferates in early Alzheimer's disease, it can help induce astroglial dysfunction and excitotoxicity.

For the proposed study, Dr. Kitazawa's team will use cultured neurons to identify mechanisms underlying the role of beta-amyloid and interleukin-1 in repressing GLT-1 activity. They will also examine how therapies designed to prevent the loss of GLT-1 may protect synapses and neurons in Alzheimer's-like mice. Results of this effort could shed new light on the consequences of astrocyte dysfunction in Alzheimer's disease.

Alzheimer's Association International Conference | July 16-20, 2017, London, England

Abstract Submissions Now Open

The Scientific Program Committee is now accepting submissions for poster
presentations, oral presentations and featured research sessions.